Shock
Methodology & AI Transparency ⓘ
Shock Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Shock happens when not enough blood and oxygen can get to your organs and tissues.
- 2 Real-world patient consensus: Clinical coding for Shock uses ICD-10 R57.9 across Heart & Vascular specialty care.
- 3 Typical cash cost range: Clinicians assessing Shock focus on coronary microvascular remodeling [Shock R57.9] and targeted history.
- 4 Top reported side effects / signs: Longitudinal Shock monitoring tracks Left Ventricular Ejection in Shock (R57.9: Fraction (LVEF)) toward 55% – 70% (R57.9).
Ask our AI Specialists anything about Shock
What Is Shock?
Shock happens when not enough blood and oxygen can get to your organs and tissues. It causes very low blood pressure and may be life-threatening. It often happens along with a serious injury. There are several kinds of shock. Hypovolemic shock happens when you lose a lot of blood or fluids. Causes include internal or external bleeding, dehydration, burns, and severe vomiting and/or diarrhea. Septic shock is caused by infections in the bloodstream. A severe allergic reaction can cause anaphylactic shock . An insect bite or sting might cause it. Cardiogenic shock happens when the heart cannot pump blood effectively. This may happen after a heart attack.
Pathophysiology, Underlying Causes & Clinical Presentation
In Shock (R57.9), physiological disruption stems from coronary microvascular remodeling [Shock R57.9], Cross-referenced with NIH MeSH (Shock), informing Heart & Cardiovascular Disease protocols that track NT-proBNP [Shock R57.9] (< 100 pg/mL (R57.9)).
Common Symptoms & Clinical Signs
- • Confusion or lack of alertness
- • Loss of consciousness
- • Presentation of Shock (R57.9): shortness of breath in Shock (R57.9: when climbing stairs)
- • Secondary Shock clinical sign: palpitations, skipped beats, in Shock (R57.9: or irregular resting)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Shock Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R57.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Left Ventricular Ejection in Shock (R57.9: Fraction (LVEF)) | 55% – 70% (R57.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: NT-proBNP [Shock R57.9] | < 100 pg/mL (R57.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [Shock R57.9] | < 14 ng/L (R57.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Shock
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Dopamine Hci Dopamine Hci Generic • RxCUI 1743938 | Catecholamine | 80% | $1.5600 | $ 71.68 /mo |
| Dextrose Monohydrate Dextrose Monohydrate Generic • RxCUI 1795514 | FDA Prescription Therapeutic Agent | 86% | $1.5100 | $ 69.66 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Shock)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Myofascial Trigger Points Release With Shockwave Therapy on Pain and Function of Background: shoulder-hand syndrome is considered a significant reason for the reduction of upper limb functions after stroke. Purpose: To investigate the influence of Myofascial Trigger Points (MTrPs) release and shockwave therapy on pain a ClinicalTrials.gov Registry (NIH NLM) • 2020-01-30 • Completed Human Clinical Trial (NCT) | N = 30 | 89/100 | PMID NCT04627636 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of early administration of tetracosactide on mortality and host response Sensitivity index underlines the quality target product profile of TCS10 in the runway of emergency casualty care. Military Medical Research • 2024-08-19 • Phase III Randomized Trial | N = 44 | 88/100 | PMID 39160574 ↗ |
| New Insights on Association of physical activity and risk of irregular heartbeat (AFib) in heart: What a 652-Participant Study Found Our current results suggest that a higher PA level associates with a lower risk of AF in HFpEF patients. Nutrition, metabolism, and cardiovascular diseases : NMCD • 2021-01-04 • Phase III Randomized Trial | N = 652 | 87/100 | PMID 33097408 ↗ |
| What the Latest Evidence Really Says About Endpoint-specific mortality associated with malignancy among adults with sepsis Malignancy was associated with higher mortality among adults with sepsis or septic shock, with variation across mortality endpoints and clinical contexts. Annals of medicine • 2026-12-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 42960561 ↗ |
| Can This Approach Help? Inside the Latest Research on Ivabradine for controlling heart rate in permanent irregular heartbeat (AFib): A Ivabradine produced a moderate rate reduction in patients with permanent irregular heartbeat (AFib). Heart rhythm • 2023-06-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37245897 ↗ |
Shock Patient Community & “People Like Me” Threads
Filter Shock community threads and patient logs by age, biological sex, dosage, and treatment duration.